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The treatment of common bile duct disorders such as biliary atresia or 91 
ischemic strictures is restricted by the lack of biliary tissue from healthy 92 
donors suitable for surgical reconstruction. Here, we report a novel method for 93 
the isolation and propagation of human cholangiocytes from the extrahepatic 94 
biliary tree in the form of Extrahepatic Cholangiocyte Organoids (ECOs) for 95 
regenerative medicine applications. The resulting ECOs closely resemble 96 
primary cholangiocytes in terms of transcriptomic profile and functional 97 
properties. We explore the regenerative potential of these organoids in vivo 98 
and demonstrate that ECOs self organize into bile duct-like tubes expressing 99 
biliary markers following transplantation under the kidney capsule of 100 
immunocompromised mice. In addition, when seeded on biodegradable 101 
scaffolds, ECOs form tissue-like structures retaining biliary characteristics. 102 
The resulting bioengineered tissue can reconstruct the gallbladder wall and 103 
repair the biliary epithelium following transplantation in a mouse injury model. 104 
Furthermore, bioengineered artificial ducts can replace the native common 105 
bile duct with no evidence of cholestasis or lumen occlusion. In conclusion, 106 
ECOs can successfully reconstruct the biliary tree providing proof-of-principle 107 
for organ regeneration using human primary cholangiocytes expanded in vitro. 108 
  109 
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Disorders of the extrahepatic bile ducts carry considerable morbidity and 110 
mortality. Indeed, 70% of pediatric liver transplantations are performed to treat 111 
biliary atresia1, Primary Sclerosing Cholangitis (PSC) alone accounts for 5% 112 
of US liver transplantations2 and biliary complications are the leading cause of 113 
graft failure following deceased liver transplantation3,4. Treatment options 114 
remain limited5,6 due to the lack of healthy donor tissue that can be used to 115 
reconstruct and replace diseased bile ducts. In vitro expansion of native 116 
cholangiocytes could address this challenge and provide cells suitable for 117 
tissue engineering applications such as biliary reconstruction. However, the 118 
culture of primary biliary epithelium remains problematic7. Here we report a 119 
novel method for the isolation and propagation of primary human 120 
cholangiocytes from the extrahepatic biliary tree, compatible with regenerative 121 
medicine applications. The resulting Extrahepatic Cholangiocyte Organoids 122 
(ECOs) express key biliary markers such as Cytokeratin 7 (KRT7 or CK7), 123 
Cytokeratin 19 (KRT19 or CK19), Gamma Glutamyl-Transferase (GGT), 124 
Cystic fibrosis transmembrane conductance regulator (CFTR) and maintain 125 
their functional properties in vitro including Alkaline Phosphatase (ALP), GGT 126 
activity and responses to secretin and somatostatin. The potential of ECOs for 127 
tissue engineering and clinical applications is further illustrated by their 128 
capacity to populate biodegradable scaffolds, organize into a functional biliary 129 
epithelium and rescue a murine model of extrahepatic biliary injury (EHBI). 130 
 131 
Results 132 
Human extrahepatic cholangiocytes can be propagated as organoids 133 
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We first focused on identifying optimal conditions to isolate primary 134 
cholangiocytes from the biliary epithelium which forms a monolayer covering 135 
the luminal surface of the biliary tree8. We tested several approaches for 136 
recovering these cells (Supplementary Fig. 1a-c) and mechanical 137 
dissociation by brushing or scraping the bile duct lumen was associated with 138 
improved survival compared to enzymatic digestion (Fig. 1a and 139 
Supplementary Fig. 1a). Furthermore, the majority of the resulting cells co-140 
expressed the biliary markers CK7 and CK19 (94.6 ± 2.4%, SD; n = 3); while 141 
no contamination from mesenchymal cell types was detected 142 
(Supplementary Fig. 1d). Consequently, mechanical dissociation constitutes 143 
the optimal method for harvesting extrahepatic cholangiocytes.  144 
To discern appropriate conditions for the maintenance and propagation 145 
of these cells, we optimized our recently established system for 3D culture of 146 
human induced pluripotent stem cell-derived intrahepatic cholangiocytes9,10. 147 
Screening of multiple growth factors known to support expansion of 148 
cholangiocytes and epithelial organoids11,12 (Supplementary Fig. 1b,c) 149 
identified the combination of Epidermal Growth Factor (EGF), R-spondin and 150 
Dickkopf-related protein 1 (DKK-1) as sufficient to promoted the growth of 151 
primary cholangiocytes into organoids (Supplementary Fig. 1c). Due to the 152 
paradoxical requirement for both a Wnt potentiator (R-spondin) and an 153 
inhibitor (DKK-1), we characterized the canonical and non-canonical/PCP Wnt 154 
pathway activity in ECOs. Our results demonstrate higher β-catenin 155 
phosphorylation in ECOs compared to cells treated with R-spondin but no 156 
DKK-1 (Supplementary Fig. 1e,f), signifying lower WNT canonical pathway 157 
activity in these cells. Furthermore ECOs exhibit higher Rho Kinase activity 158 
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compared to cells treated with R-spondin but no DKK-1 (Supplementary Fig. 159 
1g), which could be consistent with enhanced non-canonical/PCP signaling in 160 
ECOs. Thus, it is possible that non-canonical Wnt signaling controls ECO 161 
expansion marking a notable difference with previous organoid culture 162 
conditions12. 163 
Under these conditions, we derived 8 different ECO lines (Fig1. a-d, 164 
Supplementary Fig. 2a-f, Supplementary Fig. 3a-e and Supplementary 165 
Table 1) from a variety of deceased donors aged from 33 to 77 years. 166 
Notably, we obtained similar results by using cholangiocytes isolated from the 167 
gallbladder or by harvesting common bile duct cholangiocytes using an 168 
Endoscopic Retrograde Cholangio-Pancreatography (ERCP) brush instead of 169 
scrapping the lumen (Supplementary Fig. 2a,b). Consequently, ECOs can 170 
be derived from different areas of the extra-hepatic biliary tree and harvested 171 
using peri-operative (dissection and scrapping) or minimally invasive (ERCP 172 
brushings) approaches. 173 
 174 
ECOs maintain key biliary markers and function in culture  175 
The resulting cells were expanded in vitro for prolonged periods of time 176 
(Supplementary Fig. 4a) while maintaining their genetic stability 177 
(Supplementary Fig 4b,c). Electron microscopy revealed the presence of 178 
characteristic ultrastructural features including cilia, microvilli and tight 179 
junctions13 (Supplementary Fig. 3c), while QPCR and immunofluorescence 180 
(IF) analyses established the expression of key biliary markers such as KRT7  181 
or CK7, KRT19 or CK19, Hepatocyte Nuclear Factor 1 beta (HNF1B), GGT, 182 
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Secretin Receptor (SCTR), sodium-dependent bile acid transporter 183 
(ASBT/SLC10A2), CFTR and SRY-box 9 (SOX9)9 (Fig. 1b,c and 184 
Supplementary Fig. 2c,d and Supplementary Fig. 3d,e). Of note, stem cell 185 
markers such as POU5F1 or OCT4, NANOG, prominin 1 (PROM1), leucine 186 
rich repeat containing G protein-coupled receptor (LGR) LGR-4/5/6; markers 187 
of non-biliary lineages including albumin (ALB), α1-antitrypsin (SERPINA1 or 188 
A1AT), keratin 18 (KRT18), pancreatic and duodenal homeobox 1 (PDX1), 189 
insulin (INS) and glucagon (GCG); and EMT markers (vimentin (VIM), snail 190 
family transcriptional repressor 1 (SNAI1) and S100 calcium binding protein 191 
A4 (S100A4) were not detected (Supplementary Fig. 5a-c). On the other 192 
hand, 98.1% ± 0.9% (SD; n = 3) of the cells co-expressed CK7 and CK19 193 
following 20 passages (Supplementary Fig. 1d) thereby confirming the 194 
presence of a near homogeneous population of cholangiocytes.  195 
Transcriptomic analyses (Fig. 1d and Supplementary Fig. 6 and 196 
Supplementary Table 2) revealed that ECOs maintain a stable gene 197 
expression profile over multiple passages (Pearson correlation coefficient for 198 
Passage 1 (P1) vs. Passage 20 (P20) r = 0.99, Supplementary Fig. 6a,b), 199 
express key biliary markers (Supplementary Fig. 6c) and cluster closely to 200 
freshly isolated cholangiocytes (Supplementary Fig. 6d) (Pearson correlation 201 
coefficient for Primary Cholangiocytes (PCs) vs. Passage 20 (P20) r = 0.92; 202 
Supplementary Fig. 6b). Gene ontology analyses confirmed enrichment of 203 
pathways characteristic for the biliary epithelium (Supplementary Fig. 6e). 204 
Considered collectively, these results demonstrate that primary 205 
cholangiocytes derived from the extrahepatic biliary tree can be expanded in 206 
vitro without losing their original characteristics. 207 
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We then further characterized ECOs by focusing on their function 208 
following long-term culture (20 passages). The biliary epithelium regulates the 209 
homeostasis of bile through the transport of ions, water and bile acids8,14. The 210 
secretory capacity of ECOs was interrogated using Rhodamine-123, a 211 
fluorescent substrate for the cholangiocyte surface glycoprotein Multidrug 212 
Resistance protein-1 (MDR1)15,16 (Fig. 2a-c). Rhodamine-123 accumulated in 213 
the ECO lumen only in the absence of the MDR-1 antagonist verapamil, 214 
thereby confirming active secretion through MDR-1 (Fig. 2a-c). Luminal 215 
extrusion of bile acids17 was also demonstrated by showing that the 216 
fluorescent bile acid Cholyl-Lysyl-Fluorescein (CLF) was actively exported 217 
from ECOs (Fig. 2d-f). Furthermore, ECO ALP and GGT activity was 218 
comparable to freshly plated primary cholangiocytes (Fig. 2g-h and 219 
Supplementary Fig. 2e,f). The response of ECOs to secretin and 220 
somatostatin was also assessed. Secretin promotes water secretion, 221 
distending the bile duct lumen, while somatostatin negates the effects of 222 
secretin18–20. Accordingly, organoids exposed to secretin increased their 223 
diameter compared to untreated controls, while somatostatin inhibited the 224 
effect of secretin (Fig. 2i-j). Our data, therefore, demonstrate that ECOs 225 
maintain their functional properties after long term culture. 226 
 227 
ECOs self-organize into bile duct like tubes after transplantation 228 
These results prompted us to investigate the potential of ECOs for in vivo use, 229 
especially regenerative medicine applications. We first characterized the 230 
potential of ECOs for in vivo engraftment and survival by transplanting cells 231 
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under the kidney capsule of NOD.Cg-Prkdcscid Il2rgtm1Wjl (NSG) mice 232 
(Supplementary Fig. 7a) for 12 weeks21. ECOs successfully engrafted 233 
forming tubular structures expressing biliary markers such as CK19 234 
(Supplementary Fig. 7b-d).  235 
Notably, no tumor formation or markers of differentiation to other 236 
lineages were detected (Supplementary Fig. 7d). Thus, ECOs appear to 237 
maintain their basic characteristics even after prolonged engraftment in vivo 238 
under the kidney capsule.  239 
 240 
ECO-populated scaffolds reconstruct the gallbladder wall 241 
To assess the potential of ECOs for tissue engineering, we first interrogated 242 
their capacity for populating polyglycolic acid (PGA) biodegradable scaffolds 243 
commonly used to provide the structural and mechanical support required for 244 
tissue reconstruction22. Indeed, PGA is one of the most widely used synthetic 245 
polymers since it does not induce inflammatory responses in the surrounding 246 
tissue; it is biodegradable; and it is more flexible and easier to process 247 
compared to natural polymers such as collagen23. To facilitate tracking of the 248 
cells, ECOs expressing Green Fluorescent Protein (GFP) were generated 249 
through viral transduction (Supplementary Fig. 8). The resulting cells were 250 
seeded on PGA scaffolds, attached to the PGA fibers after 24-48 hours and 251 
continued to grow for 4 weeks until the scaffold was confluent (Fig. 3a-d). Of 252 
note, primary cholangiocytes grown in 2D conditions demonstrated limited 253 
expansion potential and failed to reach confluency when seeded on the 254 
scaffolds (Supplementary Fig. 9), suggesting that the proliferative capacity of 255 
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ECOs is crucial for successful scaffold colonization. The populated PGA 256 
scaffolds (Fig. 3b,c), could easily be handled with forceps and divided into 257 
smaller pieces with a surgical blade. Furthermore, the cells populating the 258 
scaffolds retained expression of biliary markers such as CK7 and CK19 (Fig. 259 
3e,f), demonstrated no evidence of epithelial–mesenchymal transition (EMT; 260 
Fig. 3e,g) and maintained their functional properties including ALP and GGT 261 
activity (Fig. 3h,i). Therefore, ECOs can populate PGA scaffolds while 262 
maintaining their functionality and marker expression thereby providing a 263 
bioengineered tissue resembling the biliary epithelium. 264 
We then decided to define the capacity of ECOs to repair the biliary 265 
epithelium. For that, we developed a mouse model of extrahepatic biliary 266 
injury (EHBI). More specifically, to simulate biliary tree wall defects requiring 267 
biliary reconstruction24, the biliary tree of healthy NSG mice was compromised 268 
through a longitudinal incision in the gallbladder wall (Fig. 4a). The surgical 269 
defect in the gallbladder wall was subsequently repaired by transplanting PGA 270 
scaffolds populated with GFP-ECOs into the injured animals (Fig. 4a-g and 271 
Supplementary Fig. 10a-f). Acellular PGA scaffolds and scaffolds populated 272 
with GFP-expressing fibroblasts (Supplementary Fig. 11a-d) were used as a 273 
negative controls. Animals receiving acellular scaffolds died within 24 hours of 274 
the operation (Fig. 4b) and post-mortem examination revealed yellow 275 
pigmentation of the peritoneal cavity and seminal vesicles  consistent with bile 276 
leak (Supplementary Fig. 10a); while all animals in the fibroblast-scaffold 277 
group failed to reconstruct their gallbladder which was replaced by fibrotic 278 
tissue incompatible with bile transport or storage (Supplementary Fig. 11e-279 
g). In contrast, animals transplanted with scaffolds containing ECOs survived 280 
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for up to 104 days without complications and were culled electively (Fig. 4b). 281 
Notably, the reconstructed gallbladders in the ECO group were fully 282 
remodeled resembling the morphology of their native counterparts (Fig. 4c 283 
and Supplementary Fig. 10b). Histology (Fig. 4d), IF and QPCR analyses of 284 
the ECO-reconstructed gallbladders (Fig. 4e and Supplementary Fig. 10c,d) 285 
unveiled integration of GFP-positive ECOs expressing biliary markers, such 286 
as KRT19, KRT7, HNF1B, SOX9, CFTR and a human-specific epitope for 287 
Ku80 (Fig. 4e and Supplementary Fig. 10c). Of note, these IF analyses also 288 
showed the presence of mouse mesenchymal cells expressing vimentin and 289 
endothelial cells expressing CD31 in the reconstructed biliary epithelium 290 
suggesting that the scaffold is colonized by endogenous cells after 291 
transplantation (Supplementary Fig. 10c). Furthermore, we also identified a 292 
population of GFP+/vimentin+/CK19- cells, suggesting that ECOs may also 293 
contribute to the scaffold stroma in vivo; possibly through EMT 294 
(Supplementary Fig. 10c,e). The integrity of the reconstructed gallbladder 295 
lumen and its exposure to bile through continuity with the biliary tree were 296 
demonstrated using magnetic resonance cholangio-pancreatography (MRCP) 297 
imaging prior to removal of the organ and was further confirmed with FITC 298 
cholangiograms (Fig. 4f,g and Supplementary Fig. 10f and Supplementary 299 
Video 1). Post mortem surgical examination and full body magnetic 300 
resonance imaging 104 days post transplantation revealed no evidence of 301 
tumor formation (Supplementary Fig. 10f and Supplementary Video 2) 302 
while IF analyses revealed no GFP+ cells in the adjacent liver tissue (data not 303 
shown). On the contrary, gallbladders reconstituted with fibroblast controls 304 
exhibited obliteration of the gallbladder lumen (Supplementary Fig. 11h,i) 305 
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and replacement of the lumen and biliary epithelium by fibroblasts expressing 306 
Fibroblast Specific Antigen S100A4 (Supplementary Fig. 11i-j). Considered 307 
collectively, our findings demonstrate the capacity of ECOs to colonize their 308 
physiological niche and regenerate part of the biliary tree without any 309 
complications. 310 
 311 
Bioengineered bile ducts replace the native mouse bile duct 312 
Reconstruction of the gallbladder wall provided proof-of-principle for the 313 
capacity of ECOs to repair the biliary epithelium after injury; however, the 314 
majority of extrahepatic bile duct disorders affect the common bile duct (CBD). 315 
Therefore, we focused on the generation of a tubular ECO-populated scaffold, 316 
which could be used for bile duct replacement surgery. The internal diameter 317 
of the mouse CBD is approximately 100μm with a wall thickness of less than 318 
50μm, which precluded the use of a PGA scaffold due to mechanical 319 
properties. Instead, we generated densified collagen tubular scaffolds (Fig. 320 
5a,b) which were populated with GFP-expressing ECOs (Fig. 5c-e). The use 321 
of densified collagen enabled the generation of constructs with an external 322 
diameter ranging from 250 to 600μm and adequate strength to maintain a 323 
patent lumen (Fig. 5d). Notably, the cells populating the collagen scaffolds 324 
maintained expression of biliary markers such as KRT19, KRT7, HNF1B, 325 
SOX9 and CFTR (Fig. 5f,g) and exhibited GGT and ALP enzymatic activity 326 
(Fig. 5h,i). Primary epithelial cells of different origin (human mammary 327 
epithelial cells; HMEC) failed to survive and adequately populate densified 328 
collagen tubes under the same conditions (Supplementary Fig. 12a). 329 
Moreover, plated HMECs failed to survive in a 10% (vol/vol) bile solution 330 
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(Supplementary Fig. 12b), further confirming the unique capacity of ECOs 331 
for generating bile resistant bio-engineered bile ducts. Collectively, these 332 
results demonstrate the capacity of ECOs for populating tubular densified 333 
collagen scaffolds without losing their original characteristics.  334 
We then decided to explore the possibility to replace the native CBD of 335 
NGS mice with a bioengineered duct consisting of an ECO-populated 336 
densified collagen tube as described above. A mid-portion of the native CBD 337 
was removed and an ECO-populated collagen tube was anastomosed end-to-338 
end to the proximal and distal duct remnants (Fig. 6a). Fibroblast populated 339 
tubes were used as a negative control. Biliary reconstruction was achieved in 340 
all animals transplanted with ECO-populated tubes (Figure 6b,c and 341 
Supplementary Fig. 13a-d), which were followed up for up to a month post 342 
transplantation (Supplementary Fig. 13d). Histology and IF and QPCR 343 
analyses (Fig. 6d-f and Supplementary Fig. 13a,b) revealed a patent lumen, 344 
with formation of a biliary epithelium by the transplanted GFP+ cells (Fig. 6e,f 345 
and Supplementary Fig 13a,b); confirmed the expression of biliary markers, 346 
such as KRT19, KRT7, HNF1B, CFTR, SOX9 (Fig. 6d,f and Supplementary 347 
Fig. 13b) by the engrafted cells; but also illustrated the presence of mouse 348 
stromal and endothelial cells (Supplementary Fig. 13b). Moreover, we 349 
observed minimal apoptosis and proliferation in the transplanted tubes 1 350 
month after transplantation, confirming the stability and integrity of the 351 
reconstituted biliary epithelium (Supplementary Fig. 13b,c). Lumen patency 352 
was further confirmed by Fluorescein Isothiocyanate (FITC) cholangiogram, 353 
MRCP and serum cholestasis marker measurements (Fig. 6g and 354 
Supplementary Fig. 13e,f and Supplementary Video 3). Accordingly 355 
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animals receiving ECO-populated tubes exhibited no elevation in serum 356 
cholestasis markers (Bilirubin, ALP; Supplementary Fig. 13e) and a patent 357 
lumen on imaging (Fig. 6g and Supplementary Fig. 13f); while the bio-358 
artificial common bile ducts retained their ALP activity in vivo (Fig. 6h).  359 
On the contrary, all fibroblast-populated collagen tubes failed due to 360 
lumen occlusion (Fig. 6b,c,e-g and Supplementary Fig. 13d), resulting in 361 
high biliary pressures and bile leak through the site of anastomosis (Fig. 6b). 362 
In conclusion, our results demonstrate the capacity of ECO-populated 363 
collagen tubes to replace the native CBD in vivo.  364 
 365 
Discussion 366 
We have demonstrated that epithelial cells from the extrahepatic biliary tree 367 
can be expanded and propagated in vitro while maintaining their 368 
cholangiocyte transcriptional signature and functional characteristics. In 369 
addition, our results show that primary cholangiocytes expanded in vitro as 370 
organoids have a unique potential for organ regeneration. Indeed, our system 371 
provides the first proof-of-principle for the application of regenerative medicine 372 
in the context of common bile duct pathology. The capacity to replace a 373 
diseased common bile duct with an in vitro bio-engineered ECO-tube could 374 
have a considerable impact for the management of disorders such as biliary 375 
atresia, which constitutes the leading cause for pediatric liver transplantation1; 376 
or ischemic strictures which are one of the most common complications 377 
following transplantation3. Consequently ECO-populated scaffolds constitute a 378 
novel system with high clinical relevance in the field of cholangiopathies. 379 
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Studies of the extrahepatic biliary epithelium have been limited by 380 
technical challenges in long-term culture and large-scale expansion of primary 381 
cholangiocytes. These challenges have so far precluded large scale 382 
experiments such as transcriptomic and genome-wide analyses which are 383 
urgently needed to better understand bile duct diseases, such as PSC and 384 
cholangiocarcinoma. The capacity of ECOs for large scale expansion, could 385 
address this challenge. Indeed, we demonstrate that starting from 105 386 
extrahepatic cholangiocytes we can generate between 1020 – 1025 cells after 387 
20 passages. Therefore, ECOs not only represent a novel source of cells for 388 
cell-based therapy but also provide a unique model system for studying the 389 
physiology and modeling disorders of the extrahepatic biliary tree in vitro. 390 
Access to human tissue constitutes a considerable limitation for 391 
systems based on primary cells. However, we show that ECOs can be 392 
obtained not only from the common bile duct but also from the gallbladder. 393 
Gallbladder tissue is easily accessible and routinely discarded following liver 394 
transplantation and cholecystectomy, one of the most common surgical 395 
procedures performed. Furthermore, in individuals not having surgery the 396 
common bile duct can be accessed using minimally invasive procedures, such 397 
as endoscopic retrograde cholangio-pancreatography (ERCP) and we 398 
demonstrate that cholangiocytes can be obtained through brushings, which 399 
are routinely performed to acquire histology specimens. Notably, no 400 
morphological or functional differences were observed between organoids 401 
obtained with these different methods. Moreover, due to the scalability of our 402 
system only a small amount of starting material is required. Finally, recent 403 
progress in replacing Matrigel by custom made hydrogels to grow gut 404 
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organoids25 suggest that translating our system from Matrigel to more 405 
clinically relevant good manufacturing practice could be feasible. Considered 406 
together, these approaches effectively address challenges of tissue 407 
availability and open the possibility of autologous as well as allogeneic cell 408 
based therapy.  409 
Notably, the derivation of primary hepatic stem cells using an organoid 410 
culture system has been reported previously12. However, the capacity of the 411 
resulting cells to differentiate into functional cholangiocytes and populate the 412 
biliary tree in vivo remains to be demonstrated. Furthermore, in vivo 413 
applications of such platforms could be restricted by contaminating stem cells 414 
with a capacity to proliferate inappropriately after transplantation and/or 415 
differentiate into non-biliary cell types. Despite the association between 416 
organoids and adult stem cells26, we never observed the expression of 417 
hepatocyte or pancreatic markers during our experiments either in vitro or 418 
after transplantation, suggesting that the differentiation capacity of ECOs is 419 
limited to their lineage of origin. Moreover, canonical WNT signaling, which is 420 
crucial for the expansion of adult stem cell organoids27 is blocked in our 421 
culture conditions through the use of DKK-1 and further studies may be 422 
required to fully elucidate the role of R-spondin in our system. Considered 423 
together, these observations suggest that our culture system does not include 424 
a stem cell population. However, we cannot completely exclude that these 425 
cells could represent a biliary progenitor population based on their ability to 426 
self-propagate and generate organoids from single cells.  427 
Of note, we have recently established a system for the generation of 428 
human pluripotent stem cell-derived cholangiocyte-like cells (CLCs)9. 429 
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However, it is worth underlining that there are considerable differences 430 
between ECOs and CLCs. CLCs correspond to intrahepatic cholangiocytes, 431 
while ECOs represent extrahepatic biliary epithelium. These two cell types are 432 
distinct in terms of embryological origin and disease involvement14 and 433 
therefore the two systems complement each other for studies of the biliary 434 
tree. Indeed, CLCs are generated following a natural path of development and 435 
maintain fetal characteristics. Therefore, they provide a unique system to 436 
study human biliary development and developmental diseases which is not 437 
possible using adult cells. However, CLCs may require a period of adjustment 438 
and further maturation in vivo, while mature, functional cells, such as ECOs, 439 
are required for coping with biliary injury in the acute setting and may be 440 
better suited for regenerative medicine applications. Furthermore, although 441 
hIPSCs provide a very good source of cells capable of generating almost any 442 
tissue, initial derivation/characterization of hIPSC lines remains time 443 
consuming; while variability in capacity of differentiation still constitutes a 444 
challenge. ECOs can be derived in less than 24 hours with a very high 445 
efficiency and can be expanded for multiple passages without losing their 446 
original characteristics. Consequently, ECOs and CLCs are comparable in 447 
terms of scalability and complementary in terms of applications, with the 448 
mature phenotype of ECOs providing a unique advantage for regenerative 449 
medicine applications in the context of tissue repair. 450 
In conclusion, our results open up novel avenues for the use of 451 
extrahepatic primary biliary tissue as a novel platform for in vitro studies, 452 




Accession codes 455 
Accession number for microarray data: E-MTAB-4591. 456 
 457 
Data availability statement 458 
The microarray data are open access and available online on ArrayExpress 459 
(https://www.ebi.ac.uk/arrayexpress/)  460 
21 
 
Acknowledgements: This work was funded by ERC starting grant Relieve 461 
IMDs (LV, NRFH), the Cambridge Hospitals National Institute for Health 462 
Research Biomedical Research Center (LV, NRFH, SaS, FS.), the Evelyn 463 
trust (NH) and the EU Fp7 grant TissuGEN (MCDB) and supported in part by 464 
the Intramural Research Program of the NIH/NIAID (RLG, CAR). FS has been 465 
supported by an Addenbrooke’s Charitable Trust Clinical Research Training 466 
Fellowship and a joint MRC-Sparks Clinical Research Training Fellowship. 467 
AWJ and AEM acknowledge the support from EPSRC (EP/L504920/1) and an 468 
Engineering for Clinical Practice Grant from the Department of Engineering, 469 
University of Cambridge. JB was supported by a BHF Studentship (Grant 470 
FS/13/65/30441). 471 
The authors would like to thank J Skepper, L Carter and the University of 472 
Cambridge Advanced Imaging Centre for their help with electron microscopy; 473 
E Farnell and the University of Cambridge, Cambridge Genomic Services for 474 
their help with microarray data processing and analysis; A Petrunkina and the 475 
NIHR Cambridge BRC Cell Phenotyping Hub for their help with cell sorting; K 476 
Burling and the MRC MDU Mouse Biochemistry Laboratory 477 
[MRC_MC_UU_12012/5] for processing mouse serum samples; R El-Khairi 478 
for her help with IF images, R Grandy for their help with providing relevant 479 
references, the Cambridge Biorepository for Translational Medicine for the 480 
provision of human tissue used in the study and Mr B McLeod for IT support. 481 
The monoclonal antibody TROMA-III developed by R Kemler was obtained 482 
from the Developmental Studies Hybridoma Bank, created by the NICHD of 483 
the NIH and maintained at The University of Iowa, Department of Biology, 484 




Author Contributions F.S. conceived and designed the study, performed 487 
experiments, acquired, interpreted and analyzed the data, developed and 488 
validated the protocols described, generated the figures and wrote  and edited 489 
the manuscript. A.W.J generated the densified collagen tubular scaffolds and 490 
conceived and developed the manufacturing technique. O.C.T. contributed to 491 
cell culture and performed animal experiments including kidney capsule 492 
injections, provision and harvesting of mouse tissue. St.S. performed the 493 
Magnetic Resonance Imaging (MRI) experiments. E.M.G. and S.S.U. 494 
reviewed and reported the MRI images. R.L.G. performed experiments 495 
including animal experiments, IF, and tissue histology. M.C.D.B. contributed 496 
to cell culture, generated viral particles, performed viral transduction 497 
experiments and generated GFP-ECOs. N.L.B. and La.V. performed animal 498 
experiments. M.J.G.-V. and P.M. performed bioinformatics analyses. D.O. 499 
performed flow cytometry analyses; L.Y. performed Western blot analyses. 500 
A.R. performed IF and QPCR analyses and provided positive controls for IF 501 
and QPCR. A.B. performed flow cytometry analyses and provided 502 
bioinformatics support. J.B. contributed to tissue histology and IF 503 
experiments. M.C.F.Z. contributed to the PGA scaffold preparation and 504 
population with cells. M.T.P. generated viral particles, performed viral 505 
transduction experiments and generated GFP-ECOs. M.P. generated viral 506 
particles. G.M.S. contributed to the scaffold generation. P.M.M. and K.E.S. 507 
maintained and provided fibroblast controls. N.P. contributed to tissue culture. 508 
N.G. and C.A.R contributed to harvesting and provision of primary tissue. I.S. 509 
performed the karyotyping and CGH analyses. S. E. D. reviewed and reported 510 
23 
 
the histology images. W.S., J.C., K.B.J., Mat.Z., Sa.S., W.T.H.G., G.J.A., 511 
S.E.B., T.A.W., T.H.K., E.M. contributed through critical revision of the 512 
manuscript for important intellectual content. N.R.F.H. contributed to the 513 
design and concept of the study and provided early study supervision. A.E.M. 514 
contributed to the design of the densified collagen scaffold and contributed 515 
through critical revision of the manuscript for important intellectual content. 516 
K.S.-P. provided primary tissue, performed animal experiments, including 517 
biliary reconstruction surgery, contributed to the design and concept of study, 518 
supervised the study, interpretated the data, wrote and edited the manuscript. 519 
L.V. Designed and conceived the study, supervised the study, interpreted the 520 
data, wrote and edited the manuscript. All the authors approved the 521 
manuscript. 522 
 523 
Conflict of financial interests statement: LV is a founder and shareholder 524 




1. Murray, K. F. & Carithers, R. L. AASLD practice guidelines: Evaluation 527 
of the patient for liver transplantation. Hepatology 41, 1407–1432 528 
(2005). 529 
2. Perkins, J. D. Are we reporting the same thing?: Comments. Liver 530 
Transplant. 13, 465–466 (2007). 531 
3. Skaro, A. I. et al. The impact of ischemic cholangiopathy in liver 532 
transplantation using donors after cardiac death: The untold story. 533 
Surgery 146, 543–553 (2009). 534 
4. Enestvedt, C. K. et al. Biliary complications adversely affect patient and 535 
graft survival after liver retransplantation. Liver Transpl. 19, 965–72 536 
(2013). 537 
5. Gallo, A. & Esquivel, C. O. Current options for management of biliary 538 
atresia. Pediatr. Transplant. 17, 95–98 (2013). 539 
6. Felder, S. I. et al. Hepaticojejunostomy using short-limb Roux-en-Y 540 
reconstruction. JAMA Surg 148, 253–7-8 (2013). 541 
7. Sampaziotis, F., Segeritz, C.-P. & Vallier, L. Potential of human induced 542 
pluripotent stem cells in studies of liver disease. Hepatology 62, 303–543 
311 (2015). 544 
8. Kanno, N., LeSage, G., Glaser, S., Alvaro, D. & Alpini, G. Functional 545 
heterogeneity of the intrahepatic biliary epithelium. Hepatology 31, 555–546 
61 (2000). 547 
9. Sampaziotis, F. et al. Cholangiocytes derived from human induced 548 
25 
 
pluripotent stem cells for disease modeling and drug validation. Nat. 549 
Biotechnol. 1–11 (2015). doi:10.1038/nbt.3275 550 
10. Sampaziotis, F. et al. Directed differentiation of human induced 551 
pluripotent stem cells into functional cholangiocyte-like cells. Nat. 552 
Protoc. 12, 814–827 (2017). 553 
11. LeSage, G., Glaser, S. & Alpini, G. Regulation of cholangiocyte 554 
proliferation. Liver 21, 73–80 (2001). 555 
12. Huch, M. et al. Long-Term Culture of Genome-Stable Bipotent Stem 556 
Cells from Adult Human Liver. Cell 160, 299–312 (2014). 557 
13. Masyuk, A. I., Masyuk, T. V & LaRusso, N. F. Cholangiocyte primary 558 
cilia in liver health and disease. Dev. Dyn. 237, 2007–12 (2008). 559 
14. Tabibian, J. H., Masyuk, A. I., Masyuk, T. V., O’Hara, S. P. & LaRusso, 560 
N. F. Physiology of cholangiocytes. Compr. Physiol. 3, 541–565 (2013). 561 
15. Cízková, D., Morký, J., Micuda, S., Osterreicher, J. & Martínková, J. 562 
Expression of MRP2 and MDR1 transporters and other hepatic markers 563 
in rat and human liver and in WRL 68 cell line. Physiol. Res. 54, 419–28 564 
(2005). 565 
16. Gigliozzi, A. et al. Molecular identification and functional 566 
characterization of Mdr1a in rat cholangiocytes. Gastroenterology 119, 567 
1113–22 (2000). 568 
17. Xia, X., Francis, H., Glaser, S., Alpini, G. & LeSage, G. Bile acid 569 




18. Caperna, T. J., Blomberg, L. A., Garrett, W. M. & Talbot, N. C. Culture 572 
of porcine hepatocytes or bile duct epithelial cells by inductive serum-573 
free media. In Vitro Cell. Dev. Biol. Anim. 47, 218–33 (2011). 574 
19. Marinelli, R. A. et al. Secretin induces the apical insertion of aquaporin-575 
1 water channels in rat cholangiocytes. Am. J. Physiol. 276, G280-6 576 
(1999). 577 
20. Gong, A.-Y. et al. Somatostatin stimulates ductal bile absorption and 578 
inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. Am. 579 
J. Physiol. Cell Physiol. 284, C1205-14 (2003). 580 
21. Ito, M. et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient 581 
mouse model for engraftment of human cells. Blood 100, 3175–82 582 
(2002). 583 
22. Chan, B. P. & Leong, K. W. Scaffolding in tissue engineering: general 584 
approaches and tissue-specific considerations. Eur. Spine J. 17, 467–585 
479 (2008). 586 
23. Cheung, H.-Y., Lau, K.-T., Lu, T.-P. & Hui, D. A critical review on 587 
polymer-based bio-engineered materials for scaffold development. 588 
Compos. Part B Eng. 38, 291–300 (2007). 589 
24. Jabłonska, B. End-to-end ductal anastomosis in biliary reconstruction: 590 
indications and limitations. Can. J. Surg. 57, 271–277 (2014). 591 
25. Gjorevski, N. et al. Designer matrices for intestinal stem cell and 592 
organoid culture. Nature 539, 560–564 (2016). 593 
26. Koo, B. K. & Clevers, H. Stem cells marked by the r-spondin receptor 594 
27 
 
LGR5. Gastroenterology 147, 289–302 (2014). 595 
27. Farin, H. F., Van Es, J. H. & Clevers, H. Redundant sources of Wnt 596 
regulate intestinal stem cells and promote formation of paneth cells. 597 
Gastroenterology 143, 1518–1529.e7 (2012). 598 
 599 
  600 
28 
 
Figure Legends 601 
 602 
Figure 1 Derivation and characterization of Extrahepatic Cholangiocyte 603 
Organoids (ECOs). (a) Schematic representation of the method used for the 604 
derivation of ECOs. (b) Quantitative real time PCR (QPCR) confirming the 605 
expression of biliary markers in Passage 1 (P1), Passage 10 (P10) and 606 
Passage 20 (P20) ECOs compared to freshly isolated Primary Cholangiocytes 607 
(PC) and Embryonic Stem  (ES) cells used as a negative control, n = 4 ECO 608 
lines. Center line, median; box, interquartile range (IQR); whiskers, range 609 
(minimum to maximum). Values are relative to the housekeeping gene 610 
Hydroxymethylbilane Synthase (HMBS) (c) Immunofluorescence (IF) 611 
analyses confirming the expression of biliary markers in ECO organoids. 612 
Scale bars, 100 μm. Single channel and higher magnification images are 613 
provided in Supplementary Fig 3. (d) Euclidean hierarchical clustering 614 
analysis comparing the transcriptome of primary cholangiocytes (Primary), 615 
passage 20 ECOs (ECO), hIPSC-derived intrahepatic cholangiocyte-like-cells 616 
(iChoLC), ES cells (ES) and hepatocytes (HEP). For each probe, standard 617 
scores (z-scores) indicate the differential expression measured in number of 618 
standard deviations from the average level across all the samples. Clusters of 619 
genes expressed in ECOs, primary cholangiocytes or both cell types are 620 
indicated. GO analyses for each cluster are provided in Supplementary Fig. 621 




Figure 2 Functional characterization of ECO organoids. (a) Fluorescence 624 
images demonstrating secretion of the MDR1 fluorescent substrate 625 
rhodamine 123 in the lumen of ECOs, which is inhibited by the MDR1 inhibitor 626 
verapamil. Scale bars, 100 μm. (b) Fluorescence intensity along the white line 627 
in a. (c) Mean intraluminal fluorescence intensity normalized to background in 628 
freshly plated Primary Cholangiocytes (Rho PC), Passage 20 ECOs (Rho 629 
P20) and P20 ECOs treated with verapamil (Ver). Error bars, Standard 630 
Deviation (SD); n = 1565 measurements in total. ****P < 0.001, Kruskal-Wallis 631 
test with Dunn’s correction for multiple comparisons. (d) Luminal extrusion of 632 
the fluorescent bile acid CLF compared to controls loaded with FITC, 633 
confirming bile acid transfer. Scale bars, 100 μm. (e) Fluorescence intensity 634 
along the white line in d. (f) Mean intra-luminal fluorescence intensity 635 
normalized over background, n = 1947 total measurements. Error bars, SD; 636 
****P < 0.001, Kruskal-Wallis test with Dunn’s correction for multiple 637 
comparisons. (g) ALP staining of ECOs. Scale bars, 500 μm (left) and 1 cm 638 
(right). (h) Mean GGT activity of P20 ECOs vs. PCs; error bars, SD; n = 3; 639 
****P < 0.001, one-way ANOVA with Dunnett’s correction for multiple 640 
comparisons. (i,j)  Mean diameter measurements (i) and live images (j) of 641 
ECOs treated with secretin or secretin and somatostatin, n = 8. Error bars, 642 
SD; ***P < 0.001; #P > 0.05 (Kruskal-Wallis test with Dunn’s correction for 643 
multiple comparisons). (a-j) Data representative of 3 different experiments. 644 
 645 
Figure 3 ECOs dissociated to single cells (ECO-SCs) can populate 646 
biodegradable PGA scaffolds. (a,b) Photographs of a PGA scaffold before (a) 647 
and after (b) treatment with ECOs. Scale bars, 1 cm. (c) Light microscopy 648 
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images of a PGA scaffold populated with ECO-SCs. Red arrowheads: Fully 649 
populated scaffold; black arrowheads: cells recruiting new PGA fibers; white 650 
arrowheads: PGA fibers. Scale bars, 100 μm. (d) Confocal microscopy 651 
images demonstrating cell expansion at different time-points after seeding of 652 
GFP-positive ECO-SCs on a PGA scaffold. White lines indicate the position of 653 
PGA fibers. Scale bars, 100 μm. (e) IF demonstrating the expression of biliary 654 
markers and lack of EMT markers in ECO-SCs seeded on PGA scaffolds. 655 
Scale bars, 100 μm (f) QPCR analyses demonstrating the expression of 656 
biliary markers in ECOs before (ECOs) and after (scaffold) seeding on PGA 657 
scaffolds, n = 4 ECO lines. Center line, median; box, interquartile range (IQR); 658 
whiskers, range (minimum to maximum). Values are relative to the 659 
housekeeping gene HMBS. (g) Mean ratio of CK7+/CK19+ and 660 
CK19+/Vimentin (VIM)+ cells in IF analyses similar to the image shown in (e). 661 
Error bars represent SD; n = 6. **P < 0.01 (Mann-Whitney test). (h) Mean 662 
GGT activity of ECO-SCs populating a PGA scaffold, n = 4. Error bars 663 
represent SD. ****P < 0.001 (two-tailed Student’s t-test). (i) ALP staining of 664 
PGA scaffolds populated by ECO-SCs. Scale bars, 500 μm. 665 
 666 
Figure 4 Biliary reconstruction in an extrahepatic biliary injury (EHBI) mouse 667 
model using ECOs. (a) Schematic representation of the method used for 668 
biliary reconstruction. (b) Kaplan–Meier survival analysis, demonstrating 669 
rescue of EHBI mice following biliary reconstruction with ECO-populated 670 
scaffolds. **P < 0.01 (log-rank test). (c) Images of gallbladders reconstructed 671 
with acellular PGA scaffolds (scaffold only), PGA scaffolds populated with 672 
ECOs (transplanted) and native un-reconstructed gallbladder controls (not 673 
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transplanted), demonstrating full reconstruction with ECO populated scaffolds. 674 
CD: cystic duct, CBD: common bile duct, CHD: common hepatic duct, F: 675 
fundus, A: anterior surface, P: posterior surface. Scale bars, 500 μm. (d) H&E 676 
staining of the reconstructed gallbladders. L: lumen. Scale bars, 100 μm (e) IF 677 
analyses demonstrating the presence of GFP-positive ECOs expressing 678 
biliary markers in the reconstructed gallbladders. L: lumen Scale bars, 100 679 
μm. Higher magnification images are provided in Supplementary Fig. 12 (f,g) 680 
FITC cholangiogram (n = 1) (f) and MRCP images (n = 2) (g) of reconstructed 681 
(transplanted) vs. native control (not transplanted) gallbladders (GB) 682 
demonstrating a patent lumen and unobstructed communication with the rest 683 
of the biliary tree. Scale bars, 1 mm (f), 5 mm (g). 684 
 685 
Figure 5 ECOs can populate densified collagen tubular scaffolds. (a) 686 
Schematic representation of the method used for the generation of densified 687 
collagen tubular scaffolds. (b) Image of a densified collagen construct prior to 688 
tube excision. Scale bar, 500 μm. (c) Maximum intensity projection image 689 
demonstrating a GFP+ ECO-populated tube after its generation. Scale bar, 30 690 
μm (d) Confocal microscopy image demonstrating lumen patency of an ECO-691 
populated collagen tube. Scale bar, 30 μm. (e) Images of a near confluent 692 
GFP+ ECO-tube. Scale bar; 100 μm. (f) IF analyses demonstrating the 693 
expression of biliary markers by ECOs following the generation of ECO-tubes. 694 
Scale bar, 100 μm. (g) QPCR analyses demonstrating the expression of 695 
biliary markers before (ECOs) and after (Scaffold) the generation of ECO-696 
populated collagen tubes. ES cells are used as a negative control, n = 4 ECO 697 
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lines. Center line, median; box, interquartile range (IQR); whiskers, range 698 
(minimum to maximum). Values are relative to HMBS expression. (h,i) ECO-699 
tubes exhibit ALP (h) and GGT (i) activity. Scale bars, 500μm; MEFs, Mouse 700 
Embryonic feeders used as negative control; Scaffold, ECO-populated, 701 
densified collagen tubes; error bars, SD; n = 3. 702 
 703 
Figure 6 Bile duct replacement using ECO-populated densified collagen 704 
tubes. (a) Schematic representation of the method used. (b) Postmortem 705 
images of mice receiving ECO-populated collagen tubes (ECOs) vs. mice 706 
receiving fibroblast-populated tubes (fibroblasts). Bile flow results in yellow 707 
pigmentation of ECO-tubes. The white color of the fibroblast conduit 708 
combined with a dilated bile-filled (yellow color) proximal bile duct (PBD) 709 
suggests luminal occlusion, resulting in bile leak (yellow peritoneal 710 
pigmentation; white dashed line). SC: Collagen tubes/scaffolds; DBD: Distal 711 
Bile Duct; scale bars, 500 μm. (c) Images of a thin walled construct 712 
resembling the native bile duct in animals receiving ECO-populated tubes vs. 713 
a thickened construct with no distinguishable lumen in animals receiving 714 
fibroblast tubes. Scale bars, 500 μm. (d) QPCR using human-specific primers 715 
confirming the expression of biliary markers by transplanted ECO-populated 716 
tubes (ECOs in vivo) compared to cultured ECOs (ECOs in vitro) and mouse 717 
biliary tissue used as a negative control, n = 4. Center line, median; box, 718 
interquartile range (IQR); whiskers, range (minimum to maximum). Values are 719 
relative to HMBS expression. (e) H&E staining demonstrating the presence of 720 
a biliary epithelium and a patent lumen in ECO-tubes but not fibroblast 721 
constructs. Scale bars, 100 μm. (f) IF analyses demonstrating a GFP+/ 722 
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CK19+ epithelium lining the lumen of ECO-constructs, vs. obliteration of the 723 
lumen by fibroblasts in fibroblast constructs. Scale bars, 100 μm. (g) FITC 724 
cholangiogram, demonstrating lumen patency in ECO-tubes vs. lumen 725 
occlusion in fibro-constructs. Scale bars, 100 μm (ECO) and 500 μm 726 
(Fibroblasts) (h) ALP activity is observed only in ECO-tubes, but not in 727 
fibroblast constructs. Scale bars, 100 μm (ECO) and 500 μm (Fibroblasts). 728 
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Online Methods 729 
Primary biliary tissue 730 
Primary biliary tissue (bile duct or gallbladder) was obtained from deceased 731 
organ donors from whom organs were being retrieved for transplantation. The 732 
gallbladder or a section of the bile duct was excised during the organ retrieval 733 
operation after obtaining informed consent from the donor’s family (REC 734 
reference numbers: 12/EE/0253, NRES Committee East of England - 735 
Cambridge Central and 15/EE/0152 NRES Committee East of England - 736 
Cambridge South). 737 
Isolation of primary cholangiocytes 738 
Excised bile duct segments were placed in a 10 cm plate and washed once 739 
with William’s E medium (Gibco, Life Technologies). A longitudinal incision 740 
was made along the wall of the excised bile duct segment exposing the lumen 741 
and 10-15 ml of William’s E medium were added to cover the tissue. The 742 
luminal epithelium was subsequently scraped off using a surgical blade, while 743 
submerged in medium. The supernatant was collected and the tissue and 744 
plate were washed 2-3 times with William’s E medium to harvest any 745 
remaining cells. The supernatant and washes were centrifuged at 444g for 4 746 
minutes. The pellet was washed with William’s E, re-centrifuged and the 747 
supernatant was discarded (Fig. 1a). 748 
Excised gallbladders were placed in a 15 cm plate, a longitudinal incision was 749 
made along the wall of the excised gallbladder and the lumen was washed 750 
once with William’s E medium (Gibco, Life Technologies). Cholangiocytes 751 
35 
 
were isolated and harvested following the method described above 752 
(Supplementary Fig. 2a). 753 
For isolation through brushings, an excised bile duct segment was placed in a 754 
10 cm plate and cannulated using an ERCP brush. The lumen was brushed 755 
10-20 times and the cells were harvested by washing the brush several times 756 
in a falcon tube containing 40-50 ml of William’s E medium (Supplementary 757 
Fig. 2b).  758 
Generation and culture of ECOs 759 
Isolated primary cholangiocytes were centrifuged at 444g for 4 minutes and 760 
re-suspended in a mixture of 66% matrigel (BD Biosciences, catalogue 761 
number: 356237) and 33% William’s E medium (Gibco, Life Technologies) 762 
supplemented with 10mM nicotinamide (Sigma-Aldrich), 17mM sodium 763 
bicarbonate (Sigma Aldrich), 0.2mM 2-Phospho-L-ascorbic acid trisodium salt 764 
(Sigma-Aldrich), 6.3mM sodium pyruvate (Invitrogen), 14mM glucose (Sigma-765 
Aldrich), 20mM HEPES (Invitrogen), ITS+ premix (BD Biosciences), 0.1µM 766 
dexamethasone (R&D Systems), 2mM Glutamax (Invitrogen),100U/ml 767 
penicillin per 100μg/ml streptomycin, 20ng/ml EGF (R&D Systems), 500ng/ml 768 
R-Spondin (R&D Systems) and 100ng/ml DKK-1 (R&D Systems). The cell 769 
suspension was plated in 24-well plate format, at 50μl/well, so that a small 770 
dome of matrigel was formed in the centre of each well and then incubated at 771 
37oC for 10-30 minutes until it solidified. Subsequently, 1ml of William’s E 772 
medium with supplements was added. The culture medium was changed 773 
every 48 hours.  774 
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To split the cells, the matrigel was digested by adding Cell Recovery Solution 775 
(Corning) for 30 minutes at 4oC. The resulting cell suspension was harvested, 776 
centrifuged at 444g for 4 minutes, washed once with William’s E medium and 777 
re-suspended in 66% matrigel and 33% William’s E medium with 778 
supplements, as described above. 779 
All experiments were performed using passage 20 ECOs unless otherwise 780 
stated. 781 
Cell line identity 782 
Demographic data for donor corresponding to the each ECO lines is provided 783 
in supplementary table 1. Following derivation ECO lines were authenticated 784 
by matching their karyotype (Supplementary Fig. 4b) to the sex of the donor 785 
of origin. The lines were tested on a regular basis and found to be negative for 786 
mycoplasma contamination.  787 
Immunofluorescence, RNA extraction and Quantitative Real Time PCR 788 
IF, RNA extraction and QPCR were performed as previously described9. A 789 
complete list of the primary and secondary antibodies used is provided in 790 
supplementary table 3. A complete list of the primers used is provided in 791 
supplementary table 4.  792 
All QPCR data are presented as the median, interquartile range (IQR) and 793 
range (minimum to maximum) of four independent ECO lines unless 794 
otherwise stated. Values are relative to the housekeeping gene 795 
Hydroxymethylbilane Synthase (HMBS). 796 
All IF images were acquired using a Zeiss Axiovert 200M inverted microscope 797 
or a Zeiss LSM 700 confocal microscope. Imagej 1.48k software (Wayne 798 
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Rasband, NIHR, USA, http://imagej.nih.gov/ij) was used for image processing. 799 
IF images are representative of 3 different experiments. IF images of 800 
reconstructed gallbladder sections are representative of 5 different animals. 801 
Microarrays 802 
RNA for microarray analysis was collected from 3 different ECO lines (n=3). 863 
The RNA was assessed for concentration and quality using a SpectroStar 864 
(BMG Labtech, Aylesbury, UK) and a Bioanalyser (Agilent Technologies, 865 
Cheadle, UK). Microarray experiments were performed at Cambridge 866 
Genomic Services, University of Cambridge, using the HumanHT-12 v4 867 
Expression BeadChip (Illumina, Chesterford, UK) according to the 868 
manufacturer’s instructions. Briefly, 200ng of Total RNA underwent linear 869 
amplification using the Illumina TotalPrep RNA Amplification Kit (Life 870 
Technologies, Paisley, UK) following the manufacturer’s instructions. The 871 
concentration, purity and integrity of the resulting cRNA were measured by 872 
SpectroStar and Bioanalyser. Finally cRNA was hybridised to the HumanHT-873 
12 v4 BeadChip overnight followed by washing, staining and scanning using 874 
the Bead Array Reader (Illumina). The microarray data are available on 875 
ArrayExpress (Accession number: E-MTAB-4591). 876 
Microarrays analysis 877 
Raw data was loaded into R using the lumi package from bioconductor28 and 878 
divided into subsets according to the groups being compared; only the 879 
samples involved in a given comparison are used. Subsets were then filtered 880 
to remove any non-expressed probes using the detection p-value from 881 
Illumina. Across all samples probes for which the intensity values were not 882 
statistically significantly different (P > 0.01) from the negative controls were 883 
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removed from the analysis. Following filtering the data was transformed using 884 
the Variance Stabilization Transformation29 from lumi and then normalised to 885 
remove technical variation between arrays using quantile normalisation. 886 
Comparisons were performed using the limma package30 with results 887 
corrected for multiple testing using False Discovery Rate (FDR) correction. 888 
Finally the quality of the data was assessed along with the correlations 889 
between samples within groups. 890 
Probes differentially expressed between HEP and ECOs representing the 891 
aggregate transcriptional “signature” of ECOs were selected for Euclidean 892 
hierarchical clustering using Perseus software (MaxQuant). Standard scores 893 
(z-scores) of the log2 normalized probe expression values across the different 894 
conditions were calculated and used for this analysis. Heatmaps and Primary 895 
Component Analysis (PCA) plots were generated using the MaxQuant 896 
Perseus software (http://www.perseus-framework.org/)31. Functional 897 
annotation and gene ontology analyses were performed on the genes 898 
differentially expressed between PCs and ECOs (Figure 1d) using the 899 
NIAID/NIH Database for Annotation, Visualization and Integrated Discovery 900 
(DAVID) v6.8 (https://david.ncifcrf.gov/)32,33. 901 
Western Analysis 902 
Total protein was extracted with lysis buffer (50mM Tris pH 8, 150mM NaCl, 903 
0.1% SDS, 0.5% sodium deoxycholate, 1% Trition X-100 and protease and 904 
phosphatase inhibitors). Protein concentrations were determined by BCA 905 
Protein Assay Kit (Thermo Fisher Scientific) according to the manufacturer’s 906 
instructions. Samples were prepared for Western blot by adding 1x NuPAGE 907 
LDS Sample Buffer with 1% β-mercaptoethanol and incubated for 5 minutes 908 
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at 95°C. Protein (25 μg) was separated by 4-12% NuPAGE Bis-Tris protein 909 
gels (Invitrogen) and transferred onto PVDF membranes (Bio-Rad). Proteins 910 
were detected by probing with antibodies specific to Phospho-β-catenin 911 
(Ser33/37/Thr41) (Cell Signalling Technology), Active-β-catenin (Millipore), 912 
Total-β-catenin (R&D), α-tubulin (Sigma) followed by incubation with 913 
horseradish peroxidase anti-mouse, anti-goat or anti-rabbit secondary 914 
antibodies. Membranes were developed using Pierce ECL Western blotting 915 
substrate (Thermo Scientific) according to the manufacturer’s instructions. 916 
The raw Western Blot images are provided in Supplementary Fig. 14. 917 
Rho Kinase activity analyses 918 
Rho Kinase activity was measured using a commercially available kit (Cell 919 
Biolabs, STA-416) according to the manufacturer’s instructions 920 
Flow cytometry analyses 921 
ECO organoids were harvested using Cell Recovery Solution (Corning) for 30 922 
minutes at 4oC, centrifuged at 444g for 4 minutes and dissociated to single 923 
cells using TrypLETM Express (Gibco).  The cells were subsequently fixed 924 
using 4% PFA for 20 minutes at 4oC. Cell staining and flow cytometry 925 
analyses were performed as previously described9,34. 926 
Karyotyping 927 
ECO organoids were harvested using Cell Recovery Solution (Corning), 928 
dissociated to single cells as described above, plated in gelatin coated plates 929 
and cultured using William’s E medium with supplements. When the cells 930 
were sub-confluent, usually after 72hrs, the cultures were incubated for 3-4 931 
hours with William’s E medium with supplements containing 0.1μg/ml 932 
colcemid (Karyomax®, Gibco). The cells were then harvested using Trypsin-933 
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EDTA (0.05%) (Gibco) for 4-5 minutes at 37oC, centrifuged at 344g for 5 934 
minutes and re-suspended in 5mls of KCl hypotonic solution (0.055M). The 935 
suspension was re-centrifuged at 344g for 5 minutes, 2 mls of a 3:1 100% 936 
methanol:glacial acetic acid solution were added and slides were prepared as 937 
previously described35 938 
Comparative Genomic Hybridization analyses 939 
Genomic DNA was labeled using the BioPrime DNA Labeling Kit (Invitrogen), 940 
according to the manufacturer’s instructions and samples were hybridised to 941 
Agilent Sureprint G3 unrestricted CGH ISCA 8x60K human genome arrays 942 
following the manufacturer’s protocol, as previously described36.  The data 943 
was analysed using the Agilent CytoGenomics Software. 944 
Rhodamine123 transport assay 945 
The Rhodamine 123 transport assay was performed as previously described9 946 
and images were acquired using a Zeiss LSM 700 confocal microscope. 947 
Fluorescence intensity was measured between the organoid interior and 948 
exterior and luminal fluorescence was normalized over the background of the 949 
extraluminal space. Each experiment was repeated in triplicate. Error bars 950 
represent SD.  951 
Cholyl-Lysyl-Fluorescein transport assay 952 
To achieve loading with Cholyl-Lysyl-Fluorescein (CLF, Corning 953 
Incorporated), ECO organoids were split in 5µM of CLF and incubated at 37oC 954 
for 30 minutes.  Images were acquired using a Zeiss LSM 700 confocal 955 
microscope and fluorescence intensity was measured between the organoid 956 
interior and exterior as described for the Rhodamine 123 transport assay. To 957 
demonstrate that the changes in CLF fluorescence intensity observed were 958 
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secondary to active export of CLF from the organoid lumen, the experiment 959 
was repeated with 5µM of unconjucated Fluorescein Isothiocyanate (FITC) 960 
(Sigma-Aldrich) as a control. Fluorescence intensity measurements were 961 
performed as described for the Rhodamine 123 transport assay. Each 962 
experiment was repeated in triplicate. Error bars represent SD.  963 
GGT activity 964 
GGT activity was measured in triplicate using the MaxDiscovery™ gamma-965 
Glutamyl Transferase (GGT) Enzymatic Assay Kit (Bioo scientific) based on 966 
the manufacturer’s instructions. Error bars represent SD.  967 
Alkaline Phosphatase staining 968 
Alkaline phosphatase was carried out using the BCIP/NBT Color 969 
Development Substrate (5-bromo-4-chloro-3-indolyl-phosphate/nitro blue 970 
tetrazolium) (Promega) according to the manufacturer’s instructions. 971 
Response to Secretin and Somatostatin 972 
Responses to secretin and somatostatin were assessed as previously 973 
described9. 974 
Generation of ECOs expressing Green Fluorescent Protein 975 
EGFP expressing VSV-G pseudotyped, recombinant HIV-1 lentiviral particles 976 
were produced with an optimized second generation packaging system by 977 
transient co-transfection of three plasmids into HEK 293T cells (ATCC CRL-978 
11268). EGFP expression is under control of a core EF1α-promoter. All 979 
plasmids were a gift from Didier Trono and obtained from addgene (pWPT-980 
GFP #12255, psPAX2 #12260, pMD2.G, #12259). Viral infection of organoids 981 
was performed as previously described37. Infected ECOs were expanded for 2 982 
passages, harvested as described above for flow cytometry analyses and cell 983 
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sorting by flow cytometry for GFP positive cells was performed. GFP 984 
expressing single cells were plated using our standard plating method and 985 
cultured in William’s E medium with supplements for 1-2 weeks until fully 986 
grown ECO organoids developed. 987 
Generation of ECO populated PGA scaffolds 988 
1mm thick PolyGlycolic Acid (PGA) scaffolds with a density of 50mg/cc were 989 
used for all experiments. Prior to seeding cells, the PGA scaffolds were pre-990 
treated with a 1M NaOH for 10-30 seconds washed 3 times, decontaminated 991 
in a 70% ethanol solution for 30 minutes and then air-dried for another 30 992 
minutes until all the ethanol had fully evaporated. All scaffolds were a gift from 993 
Dr Sanjay Sinha and obtained from Biomedical Structures (Biofelt). 994 
ECOs were harvested and dissociated to single cells as previously described 995 
for flow cytometry analyses. 5-10x106 cells were re-suspended in 100 μl of 996 
William’s E medium with supplements, seeded on a scaffold surface area of 997 
1cm2 and incubated at 37oC for 30-60 minutes to allow the cells to attach to 998 
the scaffold. The scaffolds were placed in wells of a 24-well plate and 999 
checked at regular intervals during this period to ensure the medium did not 1000 
evaporate. If necessary, 10-20 μl of William’s E medium with supplements 1001 
were added. After 1 hour, 2-3 mls of William’s E medium with supplements 1002 
were added to the wells and the medium was changed twice weekly. 1003 
Generation of densified collagen tubes 1004 
Densified collagen tubes were prepared using a novel approach. A 3D printed 1005 
chamber was fabricated, consisting of a funnel piece and a base plate. A 1006 
250μm thick metallic wire was mounted into the base plate and fed through 1007 
the centre of the funnel. Absorbent paper towels were compacted between 1008 
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the two 3D printed parts, which were then screwed together. 5 mg mL-1 1009 
collagen gel solution, loaded with cells, was poured into the funnel and gelled 1010 
at 37ºC for 30 min. After that time, the screws were loosened and, by placing 1011 
the 3D printed chambers at 37ºC for 2-4h, water was drawn out of the 1012 
collagen gel. A cell-loaded densified collagen tube was thus formed with a 1013 
250μm lumen and a wall thickness of 30-100 μm, determined by the duration 1014 
of the drying phase. Upon removal from the chamber, the tube was trimmed 1015 
for excess collagen and cut to the required length. 1016 
Culture of Human Mammary Epithelial Cells (HMECs) 1017 
HMECs and the required tissue culture consumables were purchased as a kit 1018 
from Lonza (cat no. cat no. CC-2551B) and the cells were cultured according 1019 
to the supplier’s instructions 1020 
Animal experiments 1021 
All animal experiments were performed in accordance with UK Home Office 1022 
regulations (UK Home Office Project License numbers PPL 80/2638 and PPL 1023 
70/8702). Immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice which 1024 
lack B, T and NK lymphocytes38 were bred in-house with food and water 1025 
available ad libitum pre- and post-procedures. A mix of male and female 1026 
animals were used, aged approximately 6-8 weeks. All the ECO-constructs 1027 
used were populated with ECOs derived from the common bile duct.  1028 
Generation of Extra-Hepatic Biliary Injury (EHBI) mouse model 1029 
To generate a model of extrahepatic biliary injury, midline laparotomy was 1030 
performed and the gallbladder was first mobilized by dividing the ligamentous 1031 
attachment connecting its fundus to the anterior abdominal wall under 1032 
isoflurane general anesthesia. A longitudinal incision was then made along 1033 
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2/3 of the length of the gallbladder, from the fundus towards Hartmann’s 1034 
pouch (neck of gallbladder).  1035 
Biliary reconstruction in EHBI mice 1036 
To reconstruct the gallbladder, a scaffold section measuring approximately 1 x 1037 
1 mm (seeded with ECOs or without ECOs in controls) was sutured as a 1038 
‘patch’ to close the defect using 4 – 6 interrupted 10’0 non-absorbable nylon 1039 
sutures under 40x magnification. The laparotomy was closed in two layers 1040 
with continuous 5’0 absorbable Vicryl sutures. The animals were given 1041 
buprenorphine (temgesic 0.1 mg/kg) analgesia as a bolus and observed every 1042 
15 minutes in individual cages until fully recovered. 1043 
8 animals underwent biliary reconstruction using an ECO-populated scaffold. 1044 
All animals survived up to 104 days without complications and were culled 1045 
electively for further analyses. Two control experiments were performed, 1046 
where the animals underwent biliary reconstruction using acellular scaffolds. 1047 
Both animals died within 24 hours from bile leak, therefore no further control 1048 
experiments were performed to minimize animal discomfort. 1049 
Bile duct replacement 1050 
The native common bile duct was divided and a short segment excised. The 1051 
populated densified collagen tube was anastomosed end-to-end, using 1052 
interrupted 10’0 nylon sutures, between the divided proximal and distal 1053 
common bile duct. A length of 5’0 nylon suture material (diameter 100 µm) 1054 
was inserted into the collagen tube and fed into the proximal and distal 1055 
common bile duct to ensure patency of the lumen during the anastomosis. 1056 
After the anastomosis was complete, the 5’0 suture was pushed into the 1057 
duodenum through the distal bile duct and was removed through an incision in 1058 
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the duodenum, which was then closed with interrupted 10’0 nylon sutures. 1059 
Lumen patency was assessed at the time of transplantation through light 1060 
microscopy and cannulation of the lumen with a 5’0 non-absorbable suture. 1061 
Transplantation was abandoned as futile in case of fully occluded tubes due 1062 
to cell infiltration. These events were considered construct/tube failure rather 1063 
than surgical complications and therefore were not censored in the survival 1064 
analysis. 1065 
Bile duct ligation 1066 
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, 1067 
ME). The mice were housed and bred in a Minimal Disease Unit at the animal 1068 
facility at Oslo University Hospital, Rikshospitalet, Oslo. All experiments were 1069 
performed on male mice between 8 and 12 weeks of age. A median 1070 
laparotomy was performed, the common bile duct exposed and ligated close 1071 
to the junction of the hepatic bile ducts. Sham operated mice underwent the 1072 
same procedure without ligation. Serum was harvested after 5 days. Alanine 1073 
transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase 1074 
(ALP) were measured in serum using an ADVIA 1800 (Siemens) at The 1075 
Central Laboratory, Norwegian School of Veterinary Science. All animal 1076 
experiments were approved by the Norwegian Food Safety Authority (project 1077 
license no FOTS 8210/15) and all animals received human care in line with 1078 
"Guide for the Care and Use of Laboratory Animals" (National Institutes of 1079 
Health Publication, 8th Edition, 2011). 1080 
Blood sample collection 1081 
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Blood was taken using a 23g needles directly from the inferior vena cava 1082 
under terminal anesthesia at the time the animals were electively culled and 1083 
transferred into 1.5ml Eppendorf tubes for further processing. 1084 
Blood sample processing 1085 
The blood samples were routinely processed by the University of Cambridge 1086 
Core biochemical assay laboratory (CBAL). All of the sample analysis was 1087 
performed on a Siemens Dimension EXL analyzer using reagents and assay 1088 
protocols supplied by Siemens. 1089 
Light microscopy imaging 1090 
Light microscopy images of excised reconstructed gallbladders were acquired 1091 
using a Leica MZFLIII fluorescence dissecting microscope. The images are 1092 
representative of 5 animals. 1093 
Cryosectioning and Histology 1094 
Excised gallbladders were fixed in 4% PFA, immersed in sucrose solution 1095 
overnight, mounted in optimal cutting temperature (OCT) compound and 1096 
stored at -80°C until sectioning. Sections were cut to a thickness of 10µm 1097 
using a cryostat microtome and mounted on microscopy slides for further 1098 
analysis 1099 
Haematoxylin and Eosin (H&E) Staining 1100 
H&E staining was performed using Sigma-Aldrich reagents according to the 1101 
manufacturer’s instructions. Briefly, tissue sections were hydrated, treated 1102 
with Meyer’s Haematoxylin solution for 5 minutes (Sigma-Aldrich), washed 1103 
with warm tap water for 15 minutes, placed in distilled water for 30-60 1104 
seconds and treated with eosin solution (Sigma-Aldrich) for 30-60 seconds. 1105 
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The sections were subsequently dehydrated and mounted using the Eukitt® 1106 
quick-hardening mounting medium (Sigma-Aldrich). Histology sections were 1107 
reviewed by an independent histopathologist with a special interest in 1108 
hepatobiliary histology (SD). 1109 
TUNEL assay 1110 
The TUNEL assay was performed using a commercially available kit (abcam, 1111 
ab66110) according to the manufacturer’s instructions. 1112 
Fluorescein Isothiocyanate (FITC) cholangiography 1113 
In situ FITC cholangiography was performed in sacrificed animals after 1114 
dissection of the gallbladder free from the adherent liver lobes, but before 1115 
surgical interruption of the extrahepatic biliary tree. The distal bile duct was 1116 
cannulated with a 23½ gauge needle and FITC injected retrogradely into the 1117 
gallbladder and images taken under a fluorescent microscope. 1118 
Magnetic Resonance Cholangio-Pancreatography (MRCP) 1119 
Magnetic resonance cholangio-pancreatography was performed after sacrifice 1120 
of the animals. MRCP was performed at 4.7T using a Bruker BioSpec 47/40 1121 
system. A rapid acquisition with relaxation enhancement sequence was used 1122 
with an echo train length of 40 echoes at 9.5ms intervals, a repetition time of 1123 
1000ms, field of view 5.84×4.18×4.18cm3 with a matrix of 256×180×180 1124 
yielding an isotropic resolution of 230 µm. The actively-decoupled four-1125 
channel mouse cardiac array provided by Bruker was used for imaging. 1126 
For the second mouse imaged, for higher signal to noise ratio to give 1127 
improved visualisation of the biliary ducts a two-dimensional sequence was 1128 
used with slightly varied parameters (24 spaced echoes at 11ms intervals to 1129 
give an effective echo time of 110ms; repetition time 5741ms; matrix size of 1130 
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256×256; field of view of 4.33×5.35cm2 yielding a planar resolution of 1131 
170×200µm2). Fifteen slices were acquired coronally through the liver and gall 1132 
bladder with a thickness of 0.6mm. For this acquisition, a volume coil was 1133 
used to reduce the impact of radiofrequency inhomogeneity. 1134 
To examine the biliary ducts and gall bladder, images were prepared by 1135 
maximum intensity projections. Structural imaging to rule out neoplastic 1136 
growths was performed using a T1-weighted 3D FLASH (fast low-angle shot) 1137 
sequence with a flip angle of 25°, repetition time of 14ms and an echo time of 1138 
7ms. The matrix was 512×256×256 with a field of view of 5.12×2.56×2.56cm3 1139 
for a final isotropic resolution of 100 µm. 1140 
The MRCP images were reviewed by 2 independent radiologists with a 1141 
special interest in hepatobiliary radiology (EMG, SU). 1142 
Statistical analyses 1143 
All statistical analyses were performed using GraphPad Prism 6. For small 1144 
sample sizes where descriptive statistics are not appropriate, individual data 1145 
points were plotted. For comparison between 2 mean values a 2-sided 1146 
Student’s t-test was used to calculate statistical significance. The normal 1147 
distribution of our values was confirmed using the D'Agostino & Pearson 1148 
omnibus normality test where appropriate. Variance between samples was 1149 
tested using the Brown-Forsythe test. For comparing multiple groups to a 1150 
reference group one-way ANOVA with Dunnett correction for multiple 1151 
comparisons was used between groups with equal variance, while the 1152 
Kruskal-Wallis test with Dunn’s correction for multiple comparisons was 1153 
applied for groups with unequal variance. Survival was compared using log-1154 
rank (Mantel-Cox) tests. Where the number of replicates (n) is given this 1155 
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refers to ECO lines or number of different animals unless otherwise stated. 1156 
Further details of the statistical analyses performed are provided in 1157 
Supplementary Table 5. 1158 
For animal experiments, group sizes were estimated based on previous study 1159 
variance. Final animal group sizes were chosen to allow elective culling at 1160 
different time point while maintaining n > 4 animals surviving past 30 days to 1161 
ensure reproducibility. No statistical methods were used to calculate sample 1162 
size. No formal randomization method was used to assign animals to study 1163 
groups. However, littermate animals from a cage were randomly assigned to 1164 
experimental or control groups by a technician not involved in the study. No 1165 
animals were excluded from the analysis. No blinding was used when only 1166 
one group of animals survived for radiology imaging. In cases, such as 1167 
gallbladders reconstructed with fibroblasts vs. ECOs where more than one 1168 
groups survived to be imaged, both radiologists reviewing the images (EG 1169 
and SU) where blinded to the method of reconstruction.  1170 
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